Skip to main navigation

Careers

About Us
Scientific Focus

Our Focus

Our Platform Technologies:
Turbo-ZM™ RMAs / ERSGs
Class 1 CF
Pipeline

Pipeline

Class 1 CF

RDEB/JEB

FAP & CRC
Scientific Documents
Investors

Overview

Press Releases

Events & Presentations

Corporate Governance

Financials and Filings

Stock Information

Analyst Coverage

Investment Inquiries

Press Releases

Overview
Press Releases
Events & Presentations
Corporate Governance
Financials & Filings
Stock Information
Analyst Coverage
Investment Inquiries

Year

Eloxx Pharmaceuticals Reports Topline Results from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients

September 14, 2022

Eloxx Pharmaceuticals Reports Second Quarter 2022 Financial and Operating Results and Provides Business Update

August 15, 2022

Eloxx Pharmaceuticals Announces Changes to Board of Directors

July 5, 2022

Eloxx Pharmaceuticals Reports First Quarter 2022 Financial and Operating Results and Provides Business Update

May 10, 2022

Eloxx Pharmaceuticals Reports Fourth Quarter 2021 Financial and Operating Results and Provides Business Update

March 31, 2022

Eloxx Pharmaceuticals Announces New Development Program for ELX-02 for the Treatment of Alport Syndrome

March 30, 2022

Eloxx Pharmaceuticals Announces Therapeutic Development Award from Cystic Fibrosis Foundation

March 29, 2022

TURBO-ZM is a trademark of Eloxx Pharmaceuticals, Inc..
©2022 Eloxx Pharmaceuticals, Inc.
Produced in the USA.
September 2022

Privacy Policy | Contact Us